A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment

References

• Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698–9
   PubMed Web of Science ®Google Scholar
• Hahn GM. Hyperthermia and Cancer. New York: Plenum Press, 1982
   Google Scholar
• Hettinga JV, Konings AW, Kampinga HH. Reduction of cellular cisplatin resistance by hyperthermia – A review. Int J Hyperthermia 1997;13:439–57
   PubMed Web of Science ®Google Scholar
• van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: Pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148–54
   PubMed Web of Science ®Google Scholar
• Kusumoto T, Holden SA, Ara G, Teicher BA. Hyperthermia and platinum complexes: Time between treatments and synergy in vitro and in vivo. Int J Hyperthermia 1995;11:575–86
   PubMed Web of Science ®Google Scholar
• Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002;99:14298–302
   PubMed Web of Science ®Google Scholar
• Zhou B, Gitschier J. hCTR1: A human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci USA 1997;94:7481–6
   PubMed Web of Science ®Google Scholar
• De Feo CJ, Aller SG, Siluvai GS, Blackburn NJ, Unger VM. Three-dimensional structure of the human copper transporter hCTR1. Proc Natl Acad Sci USA 2009;106:4237–42
   PubMed Web of Science ®Google Scholar
• Eisses JF, Kaplan JH. The mechanism of copper uptake mediated by human CTR1: A mutational analysis. J Biol Chem 2005;280:37159–68
   PubMed Web of Science ®Google Scholar
• Dancis A, Haile D, Yuan DS, Klausner RD. The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake. J Biol Chem 1994;269:25660–7
   PubMed Web of Science ®Google Scholar
• Petris MJ, Smith K, Lee J, Thiele DJ. Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem 2003;278:9639–46
   PubMed Web of Science ®Google Scholar
• Larson CA, Blair BG, Safaei R, Howell SB. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 2009;75:324–30
   PubMed Web of Science ®Google Scholar
• Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004;3:1543–9
   PubMed Web of Science ®Google Scholar
• Sinani D, Adle DJ, Kim H, Lee J. Distinct mechanisms for Ctr1-mediated copper and cisplatin transport. J Biol Chem 2007;282:26775–85
   PubMed Web of Science ®Google Scholar
• Guo Y, Smith K, Petris MJ. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: Requirement for the extracellular methionine-rich clusters. J Biol Chem 2004;279:46393–9
   PubMed Web of Science ®Google Scholar
• Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010;17:574–83
   PubMed Web of Science ®Google Scholar
• Lee YY, Choi CH, Do IG, Song SY, Lee W, Park HS, et al. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol Oncol 2011;122:361–5
   PubMed Web of Science ®Google Scholar
• Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, et al. Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther 2012;11:2483–94
   PubMed Web of Science ®Google Scholar
• Ashino T, Sudhahar V, Urao N, Oshikawa J, Chen GF, Wang H, et al. Unexpected role of the copper transporter ATP7A in PDGF-induced vascular smooth muscle cell migration. Circ Res 2010;107:787–99
   PubMed Web of Science ®Google Scholar
• Moreno-Altamirano MM, Aguilar-Carmona I, Sanchez-Garcia FJ. Expression of GM1, a marker of lipid rafts, defines two subsets of human monocytes with differential endocytic capacity and lipopolysaccharide responsiveness. Immunology 2007;120:536–43
   PubMed Web of Science ®Google Scholar
• Mace TA, Zhong L, Kilpatrick C, Zynda E, Lee CT, Capitano M, et al. Differentiation of CD8 + T cells into effector cells is enhanced by physiological range hyperthermia. J Leukoc Biol 2011;90:951–62
   PubMed Web of Science ®Google Scholar
• Mace TA, Zhong L, Kokolus KM, Repasky EA. Effector CD8 + T cell IFN-gamma production and cytotoxicity are enhanced by mild hyperthermia. Int J Hyperthermia 2012;28:9–18
   PubMed Web of Science ®Google Scholar
• Kitada N, Takara K, Minegaki T, Itoh C, Tsujimoto M, Sakaeda T, et al. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol 2008;62:577–84
   PubMed Web of Science ®Google Scholar
• Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, et al. Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64:4040–8
   PubMed Web of Science ®Google Scholar
• Minami T, Ichii M, Okazaki Y. Comparison of three different methods for measurement of tissue platinum level. Biol Trace Elem Res 1995;48:37–44
   PubMed Web of Science ®Google Scholar
• Yatvin MB, Cramp WA. Role of cellular membranes in hyperthermia: Some observations and theories reviewed. Int J Hyperthermia 1993;9:165–85
   PubMed Web of Science ®Google Scholar
• Hayat H, Friedberg I. Heat-induced alterations in cell membrane permeability and cell inactivation of transformed mouse fibroblasts. Int J Hyperthermia 1986;2:369–78
   PubMedGoogle Scholar
• Wu XR. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005;5:713–25
   PubMed Web of Science ®Google Scholar
• Griffiths TR. Current perspectives in bladder cancer management. Int J Clin Pract 2012;67:435–48
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270–6
   PubMed Web of Science ®Google Scholar
• Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005;16:585–9
   PubMed Web of Science ®Google Scholar
• Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004;63:466–71
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Da Pozzo LF, Naspro R, Freschi M, Paroni R, et al. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: Preliminary clinical experience. Crit Rev Oncol Hematol 2003;47:127–39
   PubMed Web of Science ®Google Scholar
• Fatehi D, van der Zee J, van der Wal E, Van Wieringen WN, Van Rhoon GC. Temperature data analysis for 22 patients with advanced cervical carcinoma treated in Rotterdam using radiotherapy, hyperthermia and chemotherapy: A reference point is needed. Int J Hyperthermia 2006;22:353–63
   PubMed Web of Science ®Google Scholar
• Kapp DS. Site and disease selection for hyperthermia clinical trials. Int J Hyperthermia 1986;2:139–56
   PubMedGoogle Scholar
• Henle KJ, Stone A, Chatterjee SK. Effect of hyperthermia on activity of three glycosyltransferases in Chinese hamster ovary cells. Cancer Res 1988;48:5717–21
   PubMed Web of Science ®Google Scholar
• Bond U, Schlesinger MJ. Ubiquitin is a heat shock protein in chicken embryo fibroblasts. Mol Cell Biol 1985;5:949–56
   PubMed Web of Science ®Google Scholar
• Maryon EB, Molloy SA, Kaplan JH. O-linked glycosylation at threonine 27 protects the copper transporter hCTR1 from proteolytic cleavage in mammalian cells. J Biol Chem 2007;282:20376–87
   PubMed Web of Science ®Google Scholar
• Maryon EB, Zhang J, Jellison JW, Kaplan JH. Human copper transporter 1 lacking O-linked glycosylation is proteolytically cleaved in a Rab9-positive endosomal compartment. J Biol Chem 2009;284:28104–14
   PubMed Web of Science ®Google Scholar
• Liu J, Sitaram A, Burd CG. Regulation of copper-dependent endocytosis and vacuolar degradation of the yeast copper transporter, Ctr1p, by the Rsp5 ubiquitin ligase. Traffic 2007;8:1375–84
   PubMed Web of Science ®Google Scholar
• Garcia-Saez AJ, Chiantia S, Schwille P. Effect of line tension on the lateral organization of lipid membranes. J Biol Chem 2007;282:33537–44
   PubMed Web of Science ®Google Scholar
• Weise K, Triola G, Janosch S, Waldmann H, Winter R. Visualizing association of lipidated signaling proteins in heterogeneous membranes – Partitioning into subdomains, lipid sorting, interfacial adsorption, and protein association. Biochim Biophys Acta 2010;1798:1409–17
   PubMed Web of Science ®Google Scholar
• Katkere B, Rosa S, Caballero A, Repasky EA, Drake JR. Physiological-range temperature changes modulate cognate antigen processing and presentation mediated by lipid raft-restricted ubiquitinated B cell receptor molecules. J Immunol 2010;185:5032–9
   PubMed Web of Science ®Google Scholar
• Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2009;35:32–46
   PubMed Web of Science ®Google Scholar
• Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62:4854–9
   PubMed Web of Science ®Google Scholar
• Khan MK, Miller MW, Taylor J, Gill NK, Dick RD, Van Golen K, et al. Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 2002;4:164–70
   PubMed Web of Science ®Google Scholar
• Moriguchi M, Nakajima T, Kimura H, Watanabe T, Takashima H, Mitsumoto Y, et al. The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer 2002;102:445–52
   PubMed Web of Science ®Google Scholar
• Yoshida D, Ikeda Y, Nakazawa S. Suppression of tumor growth in experimental 9L gliosarcoma model by copper depletion. Neurol Med Chir (Tokyo) 1995;35:133–5
   PubMedGoogle Scholar
• Brem SS, Zagzag D, Tsanaclis AM, Gately S, Elkouby MP, Brien SE. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 1990;137:1121–42
   Google Scholar
• Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6:1–10
   PubMed Web of Science ®Google Scholar
• Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9:1666–72
   PubMed Web of Science ®Google Scholar
• Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ, Brewer G, et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 2006;71:168–75
   PubMed Web of Science ®Google Scholar
• Brem S, Grossman SA, Carson KA, New P, Phuphanich S, Alavi JB, et al. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol 2005;7:246–53
   PubMed Web of Science ®Google Scholar